TNDMHealthcare · Medical DevicesThe 25 Wall Street analysts covering Tandem Diabetes Care, Inc. hold a median 12-month price target of $26 — +62.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 14 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Tandem Diabetes Care, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (90): Sales and profits are climbing, and climbing faster than before.
Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TNDM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +62.4% from it.
Of the 20 most recent actions, 1 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | Barclays | Initiates | Equal-Weight | $18 |
| 30 Sept 2026 | Citigroup | Maintains | Neutral | $24 → $20 |
| 24 Sept 2026 | Truist Securities | Maintains | Buy | — |
| 24 Sept 2026 | Truist Securities | Maintains | Buy | $31 → $28 |
| 21 Aug 2026 | William Blair | Initiates | Outperform | — |
| 21 Aug 2026 | William Blair | Initiates | Outperform | — |
| 7 Aug 2026 | Citigroup | Maintains | Neutral | — |
| 7 Aug 2026 | Citigroup | Maintains | Neutral | $17 → $21 |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | $30 → $26 |
| 28 July 2026 | UBS | Assumes | Neutral | $22 → $18 |
| 15 July 2026 | Mizuho | Maintains | Neutral | $24 → $20 |
| 15 July 2026 | Mizuho | Maintains | Neutral | — |
| 23 June 2026 | Deutsche Bank | Initiates | Hold | $16 |
| 23 June 2026 | Deutsche Bank | Initiates | Hold | — |
| 1 June 2026 | Wells Fargo | Upgrade | Overweight | — |
| 28 May 2026 | Citigroup | Maintains | Neutral | — |
| 18 May 2026 | B of A Securities | Maintains | Neutral | — |
| 12 May 2026 | Benchmark | Initiates | Hold | — |
| 11 May 2026 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TNDM appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Tandem Diabetes Care, Inc. returned +11.3% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 66% of US stocks
Cheaper than 10% of US stocks
Cheaper than 95% of US stocks
Higher than 41% of US stocks
Higher than 70% of US stocks
Higher than 27% of US stocks
Higher than 23% of US stocks
Higher than 22% of US stocks
Higher than 36% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Tandem Diabetes Care, Inc. has a market value of $1.2B and an enterprise value of $1.4B.
Revenue in the twelve months to 30 June 2026: $1.0B. The latest quarter grew 5.8% year on year.
Net income over the same four quarters: −$63.3M, a −6.1% net margin.
Diluted earnings per share, trailing twelve months: $−0.93.
Free cash flow in the twelve months to 30 June 2026: −$61.7M.
Trailing P/E: −5.5×; forward P/E: 104.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Tandem Diabetes Care, Inc. employs 2,500 people — $417K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Tandem Diabetes Care, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks says Tandem Diabetes is advancing next-generation insulin delivery technology and expanding internationally, while competition and supply constraints challenge growth.
Why it matters — These developments and constraints could affect the company’s growth and are relevant to investors following TNDM.
Tandem Diabetes Care plans to release its third quarter 2026 financial results after market close on November 5, 2026, followed by a conference call and live webcast at 4:30 pm Eastern Time to discuss its financial and operating results.
Why it matters — TNDM watchers will gain insight into the company's third quarter financial and operating performance when it reports results and hosts its earnings call on November 5, 2026.
Tandem Diabetes Care announced that its Tandem Mobi automated insulin delivery system with Control-IQ+ technology is now available in 12 international markets. The company highlighted the expanded commercial availability of the system.
Why it matters — Expanded international availability of a key product could broaden Tandem's market reach and support demand for its automated insulin delivery systems.
Tandem Diabetes Care (TNDM) was a big mover in the last session on higher-than-average trading volume, with its stock rising 7.7%. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Why it matters — A TNDM watcher would care because the earnings estimate revision trend and strong trading moves may signal continued momentum in the near term.
Zacks Investment Research published an article recommending investors retain Tandem Diabetes stock, citing the company's expanding insulin pump lineup and pay-as-you-go model as supporting growth prospects. The article also notes that macro and competitive pressures remain for the company.
Why it matters — TNDM watchers would care because the article outlines the key growth drivers behind the pump maker's prospects while acknowledging the ongoing macro and competitive headwinds that could affect performance.
The 25 Wall Street analysts covering Tandem Diabetes Care, Inc. have a median 12-month price target of $26, with estimates ranging from $18 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 25 analysts covering Tandem Diabetes Care, Inc., 14 rate it a Buy, 11 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tandem Diabetes Care, Inc. 63 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Tandem Diabetes Care, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (90 of 100).
No one can know that. What the data says: the median 12-month target from 25 analysts implies +62.4% from the last close, and Ticker Nerd's factor model ranks Tandem Diabetes Care, Inc. 63 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Tandem Diabetes Care, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNDM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $50 over the next 12 months.
Tandem Diabetes Care, Inc. returned +11.3% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Tandem Diabetes Care, Inc. is a medical device company focused on diabetes management technology.
The most recent item we track (Zacks Investment Research, 9 Oct 2026): "Is it the Right Time to Hold TNDM Stock in Your Portfolio?". Zacks says Tandem Diabetes is advancing next-generation insulin delivery technology and expanding internationally, while competition and supply constraints challenge growth.
Tandem Diabetes Care, Inc. is a medical device company focused on diabetes management technology. Tandem Diabetes Care develops and commercializes automated insulin delivery systems designed for people living with insulin-dependent diabetes, with its current product portfolio centered on the t:slim X2 insulin pump and the Tandem Mobi insulin pump. The company’s systems integrate Control-IQ technology and work with compatible continuous glucose monitors to help automate insulin delivery and support day-to-day glucose management. Tandem Diabetes Care also provides related products and services such as infusion sets, cartridges, software updates, data management tools, and mobile applications that support pump users and healthcare providers. Its offerings are used in the United States and in international markets, positioning the company as a specialized player in the broader diabetes care and medical technology sector.
CEO Mr. John F. Sheridan · 2,500 employees · United States · https://www.tandemdiabetes.com
